Navigation Links
Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
Date:4/5/2013

CHICAGO, April 5, 2013 /PRNewswire/ -- Today, Zacks Equity Research discusses the U.S. Pharma & Biotech, including Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Biogen (Nasdaq: BIIB), Amgen (Nasdaq: AMGN) and Osiris Therapeutics (Nasdaq: OSIR).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

A synopsis of today's Industry Outlook is presented below. The full article can be read at  

Link: http://www.zacks.com/commentary/26611/pharma-amp-biotech-stock-outlook-apr-2013

We continue to have a Neutral outlook on large-cap pharma stocks. While the companies will continue to face challenges like EU austerity measures and genericization, the pharma industry should be out of the worst of the genericization phase from 2013.

Several companies which had faced generic headwinds in the last couple of years should see their results recover from 2013. Cost-cutting, downsizing, streamlining of the pipeline, growth in emerging markets and product approvals should support growth.

Zacks Rank #2 (Buy) stocks in the pharma sector include Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), among others. Despite the presence of generic competition for key products, share buybacks and cost control should help Eli Lilly achieve its 2013 guidance.

In the biotech space, we are positive on Biogen (Nasdaq: BIIB). We are optimistic on Tecfidera, the company's oral multiple sclerosis drug which gained approval last week. Key products, Avonex and Tysabri, should continue contributing significantly to sales. The company is also progressing with its hemophilia pipeline.

We are also positive on Amgen (Nasdaq: AMGN). Amgen's 2013 guidance was above expectations. The company also provided an update on its long-term strategy. Amgen should be able to deliver on its long-term strategy based on expansion in key markets, launch of new manufacturing technologies, and pipeline development. Enbrel should continue performing well. Amgen's late-stage pipeline is also moving along.

Both Biogen and Amgen are Zacks Rank #2 stocks. Gilead, another Zacks Rank #2 stock, continues to do well in the HIV segment.

Osiris Therapeutics (Nasdaq: OSIR), a stem cell company, currently carries a Zacks Rank #1 (Strong Buy). Prochymal's approval in Canada and New Zealand were major milestones for the company. Meanwhile, the Biosurgery segment is also gaining traction. A partnership deal for Prochymal would be a major boost for the stock.

Among generic companies, Mylan carries a Zacks Rank #2. We are encouraged by Mylan's geographic reach and product depth and robust generic product pipeline.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks . As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
4. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
5. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
9. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
10. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
11. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its acquisition ... care service center company based in Chantilly, ... management programs for leading pharmaceutical manufacturers and health care ... will join Envoy Health Management, LLC , as ... firms, and other service companies. Together, WRB and EnvoyHealth ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... ... Viewers likely know Rob Lowe from such 80s hits as St. Elmo’s Fire and ... The West Wing and Parks and Recreation. But recently, Lowe’s leant his talents to ... on important modern-day issues that face today’s society. One of the most recent episodes ...
(Date:5/27/2017)... ... May 27, 2017 , ... Hate visiting the dentist? You should go twice per ... take care of your teeth at home. Here are some dental tips to help out: ... a small toothbrush in your work desk or a locker at school for a quick ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare ... three-day event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... and network of independent hearing healthcare providers to help them stay ahead in the ...
(Date:5/26/2017)... ... ... Mediaplanet is proud to announce the launch of its newest edition of ... on how to take care of all aspects of their skin. , On the ... with the Stars professional, Witney Carson, shares her journey with the disease that nearly ...
(Date:5/26/2017)... ... 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, and ... 31st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
Breaking Medicine News(10 mins):